Kyrbax (menadione)
/ Assertio
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
March 08, 2025
A Novel Mutation Associated with Reducing Body Myopathy
(AAN 2025)
- "This is the first reported case of RBM associated with the variant c.401A>C, p.Gln134Pro. With a wide spectrum of possible clinical presentations seen with RBM and FHL1 mutations, muscle biopsy remains a valuable diagnostic tool for genotype-phenotype correlation as newly identified variants are discovered."
Gastrointestinal Disorder • Myositis • Respiratory Diseases • PDLIM4
August 25, 2022
Culturomics of Bacteria from Radon-Saturated Water of the World's Oldest Radium Mine.
(PubMed, Microbiol Spectr)
- "This healing water, which is approximately 13 thousand years old, is used under medical supervision for the treatment of patients with neurological and rheumatic disorders. Our culturomic approach using low concentrations of growth substrates or the environmental matrix itself (i.e., water filtrate) in culturing media combined with prolonged cultivation time resulted in the isolation of a broad spectrum of microorganisms from 4 radioactive springs of Jáchymov which are phylogenetically novel and/or bear various adaptive or coping mechanisms to thrive under selective pressure and can thus provide a wide spectrum of capabilities potentially exploitable in diverse scientific, biotechnological, or medical disciplines."
Journal • Rheumatology
November 29, 2021
Anharmonicity and Spectra-Structure Correlations in MIR and NIR Spectra of Crystalline Menadione (Vitamin K).
(PubMed, Molecules)
- "For example, the theoretical calculations reliably reconstructed numerous overtones and combination bands in the 4000-3600 and 2800-1800 cm ranges. These results, provide a comprehensive origin of the fundamentals, overtones and combination bands in the NIR and MIR spectra of menadione, and the relationship of these spectral features with the molecular structure."
Journal
November 10, 2021
Redox Ticklers and Beyond: Naphthoquinone repository in the spotlight against inflammation and associated maladies.
(PubMed, Pharmacol Res)
- "Owing to the ability of naphthoquinones and its derivatives to perturb redox balance in a cell and modulate redox signaling, they have been in epicenter of drug development for plausible utilization in multiple clinical settings. The present review highlights the potential of 1,4-naphthoquinone and its natural derivatives (plumbagin, juglone, lawsone, menadione, lapachol and β-lapachone) as redox modifiers with anti-inflammatory, anti-cancer, anti-diabetic and anti-microbial activities for implication in therapeutic settings."
Journal • Review • Immunology • Inflammation • Oncology
July 07, 2021
Confirmation of unknown additives in enrofloxacin powder
(PubMed, Se Pu)
- "In this paper, the non-targeted analysis of unknown substances using UPLC-PDA combined with UPLC-TOF-HRMS is described in detail. The results may provide a technical reference for screening and identifying illegal additives in drugs, food, health care products, cosmetics, and pesticides."
Journal • Hematological Disorders • Infectious Disease • Septic Shock
April 22, 2021
Exposure to a sublethal menadione concentration modifies the mycelial secretome and conidial enzyme activities of Metarhizium anisopliae sensu lato and increases its virulence against Rhipicephalus microplus.
(PubMed, Microbiol Res)
- "Overall, supplementation with MND in the solid medium made conidia more efficient at controlling R. microplus larvae, especially by increasing, inside the conidia, the activity of some infection-related enzymes. In the liquid medium (a consolidated study model that mimics some infection conditions), proteins were up- and/or exclusively-regulated in the presence of MND, which opens a spectrum of new targets for further study to improve biological control of ticks using Metarhizium species."
Journal • Infectious Disease • CAT
November 13, 2020
Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
(clinicaltrials.gov)
- P1; N=18; Completed; Sponsor: Spectrum Pharmaceuticals, Inc; Active, not recruiting ➔ Completed
Clinical • Trial completion
1 to 7
Of
7
Go to page
1